DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of i… Read more
DBV Technologies (DBVT) - Total Assets
Latest total assets as of September 2025: $110.50 Million USD
Based on the latest financial reports, DBV Technologies (DBVT) holds total assets worth $110.50 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DBV Technologies - Total Assets Trend (2011–2024)
This chart illustrates how DBV Technologies’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DBV Technologies - Asset Composition Analysis
Current Asset Composition (December 2024)
DBV Technologies's total assets of $110.50 Million consist of 67.6% current assets and 32.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.4% |
| Accounts Receivable | $10.39 Million | 15.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $40.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how DBV Technologies's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DBV Technologies's current assets represent 67.6% of total assets in 2024, a decrease from 91.9% in 2011.
- Cash Position: Cash and equivalents constituted 49.4% of total assets in 2024, down from 73.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 15.8% of total assets.
DBV Technologies Competitors by Total Assets
Key competitors of DBV Technologies based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
DBV Technologies - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - DBV Technologies generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - DBV Technologies is currently not profitable relative to its asset base.
DBV Technologies - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.80 | 2.22 | 3.93 |
| Quick Ratio | 1.80 | 2.22 | 3.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $39.40 Million | $ 37.85 Million | $ 154.66 Million |
DBV Technologies - Advanced Valuation Insights
This section examines the relationship between DBV Technologies's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.81 |
| Latest Market Cap to Assets Ratio | 17.15 |
| Asset Growth Rate (YoY) | -64.1% |
| Total Assets | $65.66 Million |
| Market Capitalization | $1.13 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values DBV Technologies's assets at a significant premium ( 17.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: DBV Technologies's assets decreased by 64.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for DBV Technologies (2011–2024)
The table below shows the annual total assets of DBV Technologies from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $65.66 Million | -64.12% |
| 2023-12-31 | $182.99 Million | -25.77% |
| 2022-12-31 | $246.52 Million | +68.48% |
| 2021-12-31 | $146.32 Million | -46.25% |
| 2020-12-31 | $272.25 Million | +0.19% |
| 2019-12-31 | $271.73 Million | +15.75% |
| 2018-12-31 | $234.76 Million | -6.20% |
| 2017-12-31 | $250.28 Million | -21.09% |
| 2016-12-31 | $317.16 Million | -22.56% |
| 2015-12-31 | $409.53 Million | +106.87% |
| 2014-12-31 | $197.96 Million | +133.45% |
| 2013-12-31 | $84.80 Million | +15.64% |
| 2012-12-31 | $73.33 Million | +175.97% |
| 2011-12-31 | $26.57 Million | -- |